

# Contents

## CHAPTER 1

### **Causes of Cancer and Opportunities for Prevention**

H. VAINIO and E. HIETANEN <sup>†</sup> . With 2 Figures .....	1
A. Cancer Burden and Health Challenge by Cancer .....	1
B. Main External Causes and Cancer Control .....	4
I. Tobacco Smoking .....	4
II. The Effect of Diet and Overweight .....	5
III. Reproductive and Hormonal Factors .....	7
IV. Viruses, Bacteria and Parasites .....	7
V. Occupational and Environmental Carcinogens .....	7
VI. Radiation .....	8
VII. Genetic and Familial Risks .....	8
C. Potential of Cancer Prevention in the Future .....	9
References .....	10

## CHAPTER 2

### **Genetic and Environmental Factors in Carcinogenesis**

K. HEMMINKI .....	13
A. Introduction .....	13
B. Cancer Models .....	14
C. Familial Cancer .....	15
D. Cancer in Twins .....	17
E. Multiple Primary Cancers .....	19
F. Cancer in Migrants .....	20
G. Conclusions .....	21
References .....	21

## CHAPTER 3

### **Genetic Pathways to Human Cancer**

H. OHGAKI, W. YASUI, and J. YOKOTA. With 6 Figures .....	25
A. Genetic Pathways to Brain Tumors .....	25
I. Astrocytic Brain Tumors .....	25
II. Oligodendrogliomas .....	27

B. Genetic Pathways to Stomach Cancer .....	28
I. Histone Deacetylation .....	29
II. Cell Cycle Regulatory Genes .....	29
III. Oncogenes and Growth Factors .....	30
IV. Tumor-Suppressor Genes .....	31
C. Genetic Pathways to Lung Cancer .....	31
D. Summary .....	35
References .....	36

## CHAPTER 4

### **Signalling Pathways as Targets in Cancer Prevention**

M.M. MANSON, L.M. HOWELLS, and E.A. HUDSON.

With 3 Figures .....	41
A. Introduction .....	41
B. MAPK Cascades and Proliferation .....	42
C. Cell Cycle Checkpoints .....	43
D. Survival Pathways – PI3K and NF- $\kappa$ B .....	44
E. Cross-Reactivity of Signalling Pathways .....	47
F. Chemoprevention by Growth Arrest or Apoptosis .....	48
G. Conclusions .....	50
Abbreviations .....	51
References .....	52

## CHAPTER 5

### **TP53 in Carcinogenesis and Cancer Prevention**

E. GORMALLY and P. HAINAUT. With 4 Figures .....	57
A. Introduction .....	57
B. TP53: Structure and Functions .....	58
I. TP53 Is a Member of a Multi-Gene Family .....	58
II. The p53 Protein Is Responsive to Many Stress Signals .....	58
III. P53 Controls Several Antiproliferative Responses .....	61
C. Alteration of TP53 in Carcinogenesis .....	62
D. TP53 and Cancer Prevention .....	64
I. TP53 Polymorphisms and Risk of Cancer .....	64
II. TP53 Mutations as “Signatures” for Carcinogenic Exposures .....	66
1. Sunlight UVs and Nonmelanoma Skin Cancers .....	66
2. Tobacco Smoke and Lung Cancer .....	67
3. Aflatoxin B1 and Liver Cancer (Hepatocellular Carcinoma) .....	67
4. C to T Transitions at CpG Sites and Cancers Linked to Inflammatory Diseases .....	68

Contents	XV
III. Detection of TP53 Mutations in Surrogate Tissues	68
IV. The p53 Protein as a Target for Pharmacological Intervention	71
1. Stabilization of p53 by Disruption of Interactions with mdm2	71
2. Pharmacological Control of p53 Protein Activity	72
E. Conclusions and Perspectives	73
References	74

## CHAPTER 6

### **Apoptosis**

B.W. STEWART. With 2 Figures	83
A. Apoptosis and the Genesis of Tumors	83
B. How Mechanism Has Been Elucidated	84
C. Apoptosis and Carcinogenesis	85
D. Cell Division and Cell Death	86
I. Interrelationships Between the Mitogenic and Apoptotic Pathways	86
II. Consequences of DNA Damage	87
E. The Regulatory Phase	88
I. The Extrinsic Pathway: Death Via Cell Surface Receptors	89
II. The Intrinsic Pathway: The Bcl-2 Family and the Role of Mitochondria	90
F. The Effector Phase	93
I. Commitment to Death: Caspase Activation	93
II. Caspase Substrates and Late Stages of Apoptosis	94
G. Subverting Apoptosis: The Road to Malignancy	95
H. Therapeutic Implications	98
I. Conclusion	100
References	100

## CHAPTER 7

### **Deficient DNA Mismatch Repair in Carcinogenesis**

P. PELTOMÄKI	107
A. DNA Mismatch Repair System in Man	107
B. Clinical Phenotypes Associated with DNA MMR Deficiency	108
I. Hereditary Nonpolyposis Colon Cancer	109
II. Sporadic Colon Cancer with MSI	111
C. Mechanisms of Cancer Development in Tumors with MMR	
Gene Defects	113
I. Mutation Frequencies in Normal and Pathological Conditions	113

II. MMR System in Mutation Avoidance: Generation of the “Mutator Phenotype” .....	114
III. Repair of Endogenous and Exogenous DNA Damage .....	116
1. Heterocyclic Amine Adducts .....	116
2. Oxidative Damage .....	117
3. Alkylation Damage .....	118
IV. Role of MMR Proteins in Genetic Recombination .....	118
E. Concluding Remarks .....	119
References .....	120

## CHAPTER 8

### **Epigenetic Changes, Altered DNA Methylation and Cancer**

F. Lyko. With 3 Figures .....	129
A. DNA Methylation Systems .....	129
B. DNA Methylation Changes During Development .....	131
C. DNA Methylation Changes During Tumorigenesis .....	132
D. DNA Methyltransferase Expression in Tumors .....	134
E. Epigenetic Mechanisms as a Therapeutic Target .....	135
References .....	137

## CHAPTER 9

### **Hormonal Carcinogenesis**

R. KAAKS .....	141
A. Sex Steroids .....	142
I. Cancers of the Breast, Endometrium, and Ovary .....	142
1. Breast .....	143
2. Endometrium .....	145
3. Ovary .....	147
II. Cancer of the Prostate .....	148
B. Insulin, and Insulin-Like Growth Factors .....	150
I. Chronic Hyperinsulinemia and Cancer Risk .....	150
II. IGF-I, IGFBP-3 and Cancer Risk .....	153
C. Concluding Remarks .....	156
References .....	156

## CHAPTER 10

### **Angiogenesis: A Promising Target for Cancer Prevention**

I.U. ALI .....	169
A. Mechanisms of Angiogenesis .....	169
I. Growth Factors and Growth Factor Receptors .....	170
II. Cell Adhesion Receptors .....	171

III. Proteases and Protease Inhibitors in Extracellular Remodeling .....	171
IV. Endogenous Inhibitors of Angiogenesis .....	172
B. Angiogenesis as a Component of Precancerous Phenotype .....	173
I. Animal Models .....	173
II. Experimental Systems .....	174
III. Human Cancers .....	175
1. Breast Cancer .....	175
2. Prostate Cancer .....	176
3. Glial Tumors .....	176
4. Other Cancers .....	177
C. Molecular Architecture of Normal Versus Tumor-Derived Vasculature .....	177
D. Angiogenesis as a Target for Chemoprevention – Potential and Challenges .....	178
References .....	180

## CHAPTER 11

### **Arachidonic Acid Pathway in Cancer Prevention**

G.J. KELLOFF and C.C. SIGMAN .....	187
A. Arachidonic Acid Metabolic Pathways Provide Molecular Targets for Cancer Preventive Intervention .....	187
I. Prostaglandin Synthetic Pathway .....	187
II. Leukotriene Synthetic Pathway .....	189
B. COX-2 and 5-LOX as Molecular Targets for Cancer Prevention ..	190
I. COX-2 as a Target for Cancer Prevention .....	190
1. COX-2 Expression in Carcinogenesis .....	190
a) Proliferation .....	191
b) Apoptosis .....	192
c) Angiogenesis .....	192
d) Invasiveness and Cell Migration .....	192
2. Epidemiological Evidence Associates Use of COX Inhibitors with Cancer Prevention .....	192
3. COX-2 Inhibitors Show Cancer Preventive Activity in Animal Models of Carcinogenesis .....	193
4. COX-2 Inhibitors Show High Promise of Cancer Preventive Activity in Clinical Intervention Studies – A Primary Target Is Regression and Prevention of the Obligate Precursor of Cancers, Intraepithelial Neoplasia .....	194
5. COX-2 Selective Inhibitors Show Low Toxicity and Have Promise of Providing Clinical Benefit in Several Chronic Diseases .....	195
II. LOX as a Target for Cancer Prevention .....	195
1. LOX Expression in Carcinogenesis .....	195

2. Experimental Data Suggest that LOX Pathway Inhibition Has Cancer Preventive Potential, Although This Evidence Is Less Extensive and Conclusive than That for COX-2	197
a) Lung	198
b) Prostate	198
c) Breast	199
d) Other Cancers – Colon, Head and Neck, Melanoma, Leukemia	199
3. Other Considerations in the Use of LOX Inhibitors for Cancer Prevention	200
C. Promising Future Research Directions on AA Metabolic Pathways in Cancer Prevention	200
References	202

## CHAPTER 12

### **Infections, Inflammation and Cancer: Roles of Reactive Oxygen and Nitrogen Species**

H. OHSHIMA and M. TATEMACHI. With 1 Figure	211
A. Introduction	211
B. Infection and Cancer-Possible Mechanisms	211
C. The Inflammatory Process	213
D. The Respiratory Burst	213
E. Production of ROS and RNS	214
F. DNA Damage by ROS and RNS	216
G. Mutations Caused by ROS and RNS	218
H. Protein Damage Induced by ROS and RNS	219
I. Protein Damage as an Epigenetic Effect of ROS and RNS in Carcinogenesis	219
J. Chemoprevention by Anti-inflammatory Agents and Antioxidants	221
K. Conclusion	222
References	222

## CHAPTER 13

### **Infections and the Etiology of Human Cancer: Epidemiological Evidence and Opportunities for Prevention**

F.X. BOSCH, S. DE SANJOSÉ, J. RIBES, and C.A. GONZÁLEZ. With 2 Figures	229
A. Cancer Burden Related to Infections	229
B. Hepatitis B and C Viruses and Liver Cancer	232
I. Opportunities for Prevention of Liver Cancer	233

C. Human Papillomavirus and Cancer of the Anogenital Tract . . . . .	235
I. HPV Type Distribution in Cervical Cancer Cases . . . . .	236
II. Risk Estimates from Case-Control Studies . . . . .	236
III. New Options for Screening and Triage in Cervical Cancer Prevention . . . . .	237
IV. Immune Response to HPV Infection and Implications for Vaccine Development . . . . .	237
D. <i>Helicobacter pylori</i> and Gastric Cancer . . . . .	238
I. Opportunities for Prevention of Gastric Cancer . . . . .	239
E. Epstein-Barr Virus, Other Infections and Malignant Lymphomas . . . . .	240
F. Epstein-Barr Virus, Nasopharyngeal Carcinoma and Other Cancers . . . . .	243
G. Cancer Incidence in HIV-Infected Persons . . . . .	244
I. Anogenital Cancer in HIV-Positive and AIDS Patients . . . . .	246
II. Opportunities for Prevention of HIV-Associated Cancers . . . . .	246
H. Conclusio . . . . .	247
References . . . . .	247

## CHAPTER 14

### **Xenobiotic Metabolism and Cancer Susceptibility**

O. PELKONEN, K. VÄHÄKANGAS, and H. RAUNIO. With 1 Figure . . . . .	253
A. Significance of Xenobiotic Metabolism in Carcinogenesis . . . . .	253
B. Carcinogen Metabolism . . . . .	254
C. Significance of DNA Binding . . . . .	255
D. Genetic Polymorphisms in Carcinogen Metabolism . . . . .	256
I. CYP1A1 and AHR . . . . .	257
II. CYP2A6 . . . . .	259
III. CYP2D6 . . . . .	260
IV. GST . . . . .	261
V. <i>N</i> -Acetyltransferases . . . . .	261
VI. Other Genes . . . . .	262
E. Xenobiotic-Metabolizing Enzymes and Chemoprevention . . . . .	263
I. Anticarcinogenic Chemicals Affecting Metabolism-Related Phenomena . . . . .	263
II. Prevention of Binding of Reactive Intermediates . . . . .	264
III. Scavenging of Radical By-Products of Metabolism . . . . .	264
IV. Inhibition/Downregulation of Carcinogen-Induced Expression of Cancer . . . . .	264
F. Identification of Individuals at Increased Risk Because of Genotype . . . . .	265
G. Conclusions . . . . .	265
References . . . . .	265

## CHAPTER 15

**Animal Models for Mechanistic Cancer Research**

Z.-Q. WANG. With 1 Figure .....	271
A. Introduction .....	271
B. Genetically Modified Mice to Study Tumor Development .....	273
C. Mouse Models for Human Tumors .....	274
I. Skin Cancer .....	274
II. Breast Cancer .....	276
1. Overexpressing Oncogenes in Mice .....	276
2. Mice Carrying Disrupted Breast Cancer Susceptibility Genes <i>BRCA1</i> and <i>BRCA2</i> .....	276
III. Liver Cancer .....	277
IV. Disruption of the Genes That Are Responsible for DNA Repair and Genomic Stability .....	278
1. Mice Deficient in p53 .....	279
2. Mice with Inactivated DNA Repair Genes .....	279
a) Mismatch Repair Genes .....	280
b) Disruption of Parp-1 .....	280
c) Genes Responsible for DNA Double-Strand Break Repair .....	281
D. Genetic Tools for Molecular Epidemiological and Environmental Carcinogenesis Studies .....	281
E. Perspectives .....	282
References .....	283

## CHAPTER 16

**New Promising Chemopreventive Agents and Mechanisms**

C. GERHÄUSER and N. FRANK. With 3 Figures .....	289
A. Introduction .....	289
B. Chemopreventive Agent Development .....	289
I. Xanthohumol .....	290
II. Lunularic Acid-Derived Bibenzyls .....	294
III. Acylphloroglucinol Derivatives .....	296
C. Novel Mechanisms of Chemopreventive Agents .....	297
I. NF- $\kappa$ B as a Molecular Target of Sulforaphane .....	297
II. Novel Antioxidant Mechanisms of Ellagic Acid .....	299
D. Conclusion .....	300
References .....	301



## CHAPTER 17

**Molecular Epidemiology in Cancer Prevention**

C.P. WILD. With 2 Figures .....	307
A. Introduction .....	307
B. Etiology .....	308
I. Assessment of Environmental Exposures .....	308
II. Genetic Susceptibility .....	311
III. Molecular Classification of Cancer .....	312
IV. Biological Plausibility .....	313
C. Screening and Surveillance .....	314
I. Genetic Markers in Screening .....	314
II. Molecular Markers in Surveillance .....	314
D. Prognosis .....	315
E. Mechanistic Basis for Chemoprevention – The Example of Aflatoxin .....	316
F. Conclusion .....	317
References .....	318
Subject Index .....	323

Mechanisms in Carcinogenesis and Cancer Prevention

Vainio, H.U.; Hietanen, E.K. (Eds.)

2003, XXI, 329 p., Hardcover

ISBN: 978-3-540-43837-3